Global Primary Sclerosing Cholangitis (Psc) Market Research Report 2025(Status and Outlook)
Report Overview
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease that primarily affects the bile ducts. The term 'sclerosing' refers to the scarring and narrowing (stricturing) of the bile ducts, which impedes the flow of bile from the liver to the small intestine. PSC is characterized by inflammation and fibrosis of the bile ducts, leading to a range of liver and digestive issues.
The global Primary Sclerosing Cholangitis (Psc) market size was estimated at USD 50.42 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 5.80% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Primary Sclerosing Cholangitis (Psc) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Primary Sclerosing Cholangitis (Psc) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Primary Sclerosing Cholangitis (Psc) market
Global Primary Sclerosing Cholangitis (Psc) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Acorda Therapeutics
Gilead Sciences
NGM Biopharmaceuticals
Intercept Pharmaceuticals
Dr. Falk Pharma
Allergan
Shire
Durect Corporation
Conatus Pharmaceuticals
Sirnaomics
Shenzhen HighTide Biopharmaceutical
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Daewoong Pharmaceutical
Mitsubishi Tanabe Pharma
Lannett
Market Segmentation (by Type)
Medical Treatement
Liver Transplantation
Others
Market Segmentation (by Application)
Hospital
Clinics
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Primary Sclerosing Cholangitis (Psc) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Primary Sclerosing Cholangitis (Psc), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease that primarily affects the bile ducts. The term 'sclerosing' refers to the scarring and narrowing (stricturing) of the bile ducts, which impedes the flow of bile from the liver to the small intestine. PSC is characterized by inflammation and fibrosis of the bile ducts, leading to a range of liver and digestive issues.
The global Primary Sclerosing Cholangitis (Psc) market size was estimated at USD 50.42 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 5.80% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Primary Sclerosing Cholangitis (Psc) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Primary Sclerosing Cholangitis (Psc) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Primary Sclerosing Cholangitis (Psc) market
Global Primary Sclerosing Cholangitis (Psc) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Acorda Therapeutics
Gilead Sciences
NGM Biopharmaceuticals
Intercept Pharmaceuticals
Dr. Falk Pharma
Allergan
Shire
Durect Corporation
Conatus Pharmaceuticals
Sirnaomics
Shenzhen HighTide Biopharmaceutical
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Daewoong Pharmaceutical
Mitsubishi Tanabe Pharma
Lannett
Market Segmentation (by Type)
Medical Treatement
Liver Transplantation
Others
Market Segmentation (by Application)
Hospital
Clinics
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Primary Sclerosing Cholangitis (Psc) Market
- Overview of the regional outlook of the Primary Sclerosing Cholangitis (Psc) Market.
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Primary Sclerosing Cholangitis (Psc) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Primary Sclerosing Cholangitis (Psc), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Primary Sclerosing Cholangitis (Psc)
1.2 Key Market Segments
1.2.1 Primary Sclerosing Cholangitis (Psc) Segment by Type
1.2.2 Primary Sclerosing Cholangitis (Psc) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Primary Sclerosing Cholangitis (Psc) Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Primary Sclerosing Cholangitis (Psc) Product Life Cycle
3.3 Global Primary Sclerosing Cholangitis (Psc) Sales by Manufacturers (2020-2025)
3.4 Global Primary Sclerosing Cholangitis (Psc) Revenue Market Share by Manufacturers (2020-2025)
3.5 Primary Sclerosing Cholangitis (Psc) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Primary Sclerosing Cholangitis (Psc) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Primary Sclerosing Cholangitis (Psc) Market Competitive Situation and Trends
3.8.1 Primary Sclerosing Cholangitis (Psc) Market Concentration Rate
3.8.2 Global 5 and 10 Largest Primary Sclerosing Cholangitis (Psc) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 PRIMARY SCLEROSING CHOLANGITIS (PSC) INDUSTRY CHAIN ANALYSIS
4.1 Primary Sclerosing Cholangitis (Psc) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Primary Sclerosing Cholangitis (Psc) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Primary Sclerosing Cholangitis (Psc) Market
5.7 ESG Ratings of Leading Companies
6 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Type (2020-2025)
6.3 Global Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Type (2020-2025)
6.4 Global Primary Sclerosing Cholangitis (Psc) Price by Type (2020-2025)
7 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Primary Sclerosing Cholangitis (Psc) Market Sales by Application (2020-2025)
7.3 Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) by Application (2020-2025)
7.4 Global Primary Sclerosing Cholangitis (Psc) Sales Growth Rate by Application (2020-2025)
8 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SALES BY REGION
8.1 Global Primary Sclerosing Cholangitis (Psc) Sales by Region
8.1.1 Global Primary Sclerosing Cholangitis (Psc) Sales by Region
8.1.2 Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region
8.2 Global Primary Sclerosing Cholangitis (Psc) Market Size by Region
8.2.1 Global Primary Sclerosing Cholangitis (Psc) Market Size by Region
8.2.2 Global Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region
8.3 North America
8.3.1 North America Primary Sclerosing Cholangitis (Psc) Sales by Country
8.3.2 North America Primary Sclerosing Cholangitis (Psc) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Primary Sclerosing Cholangitis (Psc) Sales by Country
8.4.2 Europe Primary Sclerosing Cholangitis (Psc) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales by Region
8.5.2 Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Primary Sclerosing Cholangitis (Psc) Sales by Country
8.6.2 South America Primary Sclerosing Cholangitis (Psc) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales by Region
8.7.2 Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET PRODUCTION BY REGION
9.1 Global Production of Primary Sclerosing Cholangitis (Psc) by Region(2020-2025)
9.2 Global Primary Sclerosing Cholangitis (Psc) Revenue Market Share by Region (2020-2025)
9.3 Global Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Primary Sclerosing Cholangitis (Psc) Production
9.4.1 North America Primary Sclerosing Cholangitis (Psc) Production Growth Rate (2020-2025)
9.4.2 North America Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Primary Sclerosing Cholangitis (Psc) Production
9.5.1 Europe Primary Sclerosing Cholangitis (Psc) Production Growth Rate (2020-2025)
9.5.2 Europe Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Primary Sclerosing Cholangitis (Psc) Production (2020-2025)
9.6.1 Japan Primary Sclerosing Cholangitis (Psc) Production Growth Rate (2020-2025)
9.6.2 Japan Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Primary Sclerosing Cholangitis (Psc) Production (2020-2025)
9.7.1 China Primary Sclerosing Cholangitis (Psc) Production Growth Rate (2020-2025)
9.7.2 China Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Acorda Therapeutics
10.1.1 Acorda Therapeutics Basic Information
10.1.2 Acorda Therapeutics Primary Sclerosing Cholangitis (Psc) Product Overview
10.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.1.4 Acorda Therapeutics Business Overview
10.1.5 Acorda Therapeutics SWOT Analysis
10.1.6 Acorda Therapeutics Recent Developments
10.2 Gilead Sciences
10.2.1 Gilead Sciences Basic Information
10.2.2 Gilead Sciences Primary Sclerosing Cholangitis (Psc) Product Overview
10.2.3 Gilead Sciences Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.2.4 Gilead Sciences Business Overview
10.2.5 Gilead Sciences SWOT Analysis
10.2.6 Gilead Sciences Recent Developments
10.3 NGM Biopharmaceuticals
10.3.1 NGM Biopharmaceuticals Basic Information
10.3.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
10.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.3.4 NGM Biopharmaceuticals Business Overview
10.3.5 NGM Biopharmaceuticals SWOT Analysis
10.3.6 NGM Biopharmaceuticals Recent Developments
10.4 Intercept Pharmaceuticals
10.4.1 Intercept Pharmaceuticals Basic Information
10.4.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
10.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.4.4 Intercept Pharmaceuticals Business Overview
10.4.5 Intercept Pharmaceuticals Recent Developments
10.5 Dr. Falk Pharma
10.5.1 Dr. Falk Pharma Basic Information
10.5.2 Dr. Falk Pharma Primary Sclerosing Cholangitis (Psc) Product Overview
10.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.5.4 Dr. Falk Pharma Business Overview
10.5.5 Dr. Falk Pharma Recent Developments
10.6 Allergan
10.6.1 Allergan Basic Information
10.6.2 Allergan Primary Sclerosing Cholangitis (Psc) Product Overview
10.6.3 Allergan Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.6.4 Allergan Business Overview
10.6.5 Allergan Recent Developments
10.7 Shire
10.7.1 Shire Basic Information
10.7.2 Shire Primary Sclerosing Cholangitis (Psc) Product Overview
10.7.3 Shire Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.7.4 Shire Business Overview
10.7.5 Shire Recent Developments
10.8 Durect Corporation
10.8.1 Durect Corporation Basic Information
10.8.2 Durect Corporation Primary Sclerosing Cholangitis (Psc) Product Overview
10.8.3 Durect Corporation Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.8.4 Durect Corporation Business Overview
10.8.5 Durect Corporation Recent Developments
10.9 Conatus Pharmaceuticals
10.9.1 Conatus Pharmaceuticals Basic Information
10.9.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
10.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.9.4 Conatus Pharmaceuticals Business Overview
10.9.5 Conatus Pharmaceuticals Recent Developments
10.10 Sirnaomics
10.10.1 Sirnaomics Basic Information
10.10.2 Sirnaomics Primary Sclerosing Cholangitis (Psc) Product Overview
10.10.3 Sirnaomics Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.10.4 Sirnaomics Business Overview
10.10.5 Sirnaomics Recent Developments
10.11 Shenzhen HighTide Biopharmaceutical
10.11.1 Shenzhen HighTide Biopharmaceutical Basic Information
10.11.2 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (Psc) Product Overview
10.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.11.4 Shenzhen HighTide Biopharmaceutical Business Overview
10.11.5 Shenzhen HighTide Biopharmaceutical Recent Developments
10.12 Glenmark
10.12.1 Glenmark Basic Information
10.12.2 Glenmark Primary Sclerosing Cholangitis (Psc) Product Overview
10.12.3 Glenmark Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.12.4 Glenmark Business Overview
10.12.5 Glenmark Recent Developments
10.13 Impax Laboratories
10.13.1 Impax Laboratories Basic Information
10.13.2 Impax Laboratories Primary Sclerosing Cholangitis (Psc) Product Overview
10.13.3 Impax Laboratories Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.13.4 Impax Laboratories Business Overview
10.13.5 Impax Laboratories Recent Developments
10.14 Mylan
10.14.1 Mylan Basic Information
10.14.2 Mylan Primary Sclerosing Cholangitis (Psc) Product Overview
10.14.3 Mylan Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.14.4 Mylan Business Overview
10.14.5 Mylan Recent Developments
10.15 Teva Pharmaceuticals
10.15.1 Teva Pharmaceuticals Basic Information
10.15.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
10.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.15.4 Teva Pharmaceuticals Business Overview
10.15.5 Teva Pharmaceuticals Recent Developments
10.16 Daewoong Pharmaceutical
10.16.1 Daewoong Pharmaceutical Basic Information
10.16.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (Psc) Product Overview
10.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.16.4 Daewoong Pharmaceutical Business Overview
10.16.5 Daewoong Pharmaceutical Recent Developments
10.17 Mitsubishi Tanabe Pharma
10.17.1 Mitsubishi Tanabe Pharma Basic Information
10.17.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (Psc) Product Overview
10.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.17.4 Mitsubishi Tanabe Pharma Business Overview
10.17.5 Mitsubishi Tanabe Pharma Recent Developments
10.18 Lannett
10.18.1 Lannett Basic Information
10.18.2 Lannett Primary Sclerosing Cholangitis (Psc) Product Overview
10.18.3 Lannett Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.18.4 Lannett Business Overview
10.18.5 Lannett Recent Developments
11 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET FORECAST BY REGION
11.1 Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast
11.2 Global Primary Sclerosing Cholangitis (Psc) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country
11.2.3 Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Region
11.2.4 South America Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Primary Sclerosing Cholangitis (Psc) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Primary Sclerosing Cholangitis (Psc) Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Primary Sclerosing Cholangitis (Psc) by Type (2026-2033)
12.1.2 Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Primary Sclerosing Cholangitis (Psc) by Type (2026-2033)
12.2 Global Primary Sclerosing Cholangitis (Psc) Market Forecast by Application (2026-2033)
12.2.1 Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) Forecast by Application
12.2.2 Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Primary Sclerosing Cholangitis (Psc)
1.2 Key Market Segments
1.2.1 Primary Sclerosing Cholangitis (Psc) Segment by Type
1.2.2 Primary Sclerosing Cholangitis (Psc) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Primary Sclerosing Cholangitis (Psc) Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Primary Sclerosing Cholangitis (Psc) Product Life Cycle
3.3 Global Primary Sclerosing Cholangitis (Psc) Sales by Manufacturers (2020-2025)
3.4 Global Primary Sclerosing Cholangitis (Psc) Revenue Market Share by Manufacturers (2020-2025)
3.5 Primary Sclerosing Cholangitis (Psc) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Primary Sclerosing Cholangitis (Psc) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Primary Sclerosing Cholangitis (Psc) Market Competitive Situation and Trends
3.8.1 Primary Sclerosing Cholangitis (Psc) Market Concentration Rate
3.8.2 Global 5 and 10 Largest Primary Sclerosing Cholangitis (Psc) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 PRIMARY SCLEROSING CHOLANGITIS (PSC) INDUSTRY CHAIN ANALYSIS
4.1 Primary Sclerosing Cholangitis (Psc) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Primary Sclerosing Cholangitis (Psc) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Primary Sclerosing Cholangitis (Psc) Market
5.7 ESG Ratings of Leading Companies
6 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Type (2020-2025)
6.3 Global Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Type (2020-2025)
6.4 Global Primary Sclerosing Cholangitis (Psc) Price by Type (2020-2025)
7 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Primary Sclerosing Cholangitis (Psc) Market Sales by Application (2020-2025)
7.3 Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) by Application (2020-2025)
7.4 Global Primary Sclerosing Cholangitis (Psc) Sales Growth Rate by Application (2020-2025)
8 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET SALES BY REGION
8.1 Global Primary Sclerosing Cholangitis (Psc) Sales by Region
8.1.1 Global Primary Sclerosing Cholangitis (Psc) Sales by Region
8.1.2 Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region
8.2 Global Primary Sclerosing Cholangitis (Psc) Market Size by Region
8.2.1 Global Primary Sclerosing Cholangitis (Psc) Market Size by Region
8.2.2 Global Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region
8.3 North America
8.3.1 North America Primary Sclerosing Cholangitis (Psc) Sales by Country
8.3.2 North America Primary Sclerosing Cholangitis (Psc) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Primary Sclerosing Cholangitis (Psc) Sales by Country
8.4.2 Europe Primary Sclerosing Cholangitis (Psc) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales by Region
8.5.2 Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Primary Sclerosing Cholangitis (Psc) Sales by Country
8.6.2 South America Primary Sclerosing Cholangitis (Psc) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales by Region
8.7.2 Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET PRODUCTION BY REGION
9.1 Global Production of Primary Sclerosing Cholangitis (Psc) by Region(2020-2025)
9.2 Global Primary Sclerosing Cholangitis (Psc) Revenue Market Share by Region (2020-2025)
9.3 Global Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Primary Sclerosing Cholangitis (Psc) Production
9.4.1 North America Primary Sclerosing Cholangitis (Psc) Production Growth Rate (2020-2025)
9.4.2 North America Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Primary Sclerosing Cholangitis (Psc) Production
9.5.1 Europe Primary Sclerosing Cholangitis (Psc) Production Growth Rate (2020-2025)
9.5.2 Europe Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Primary Sclerosing Cholangitis (Psc) Production (2020-2025)
9.6.1 Japan Primary Sclerosing Cholangitis (Psc) Production Growth Rate (2020-2025)
9.6.2 Japan Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Primary Sclerosing Cholangitis (Psc) Production (2020-2025)
9.7.1 China Primary Sclerosing Cholangitis (Psc) Production Growth Rate (2020-2025)
9.7.2 China Primary Sclerosing Cholangitis (Psc) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Acorda Therapeutics
10.1.1 Acorda Therapeutics Basic Information
10.1.2 Acorda Therapeutics Primary Sclerosing Cholangitis (Psc) Product Overview
10.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.1.4 Acorda Therapeutics Business Overview
10.1.5 Acorda Therapeutics SWOT Analysis
10.1.6 Acorda Therapeutics Recent Developments
10.2 Gilead Sciences
10.2.1 Gilead Sciences Basic Information
10.2.2 Gilead Sciences Primary Sclerosing Cholangitis (Psc) Product Overview
10.2.3 Gilead Sciences Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.2.4 Gilead Sciences Business Overview
10.2.5 Gilead Sciences SWOT Analysis
10.2.6 Gilead Sciences Recent Developments
10.3 NGM Biopharmaceuticals
10.3.1 NGM Biopharmaceuticals Basic Information
10.3.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
10.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.3.4 NGM Biopharmaceuticals Business Overview
10.3.5 NGM Biopharmaceuticals SWOT Analysis
10.3.6 NGM Biopharmaceuticals Recent Developments
10.4 Intercept Pharmaceuticals
10.4.1 Intercept Pharmaceuticals Basic Information
10.4.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
10.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.4.4 Intercept Pharmaceuticals Business Overview
10.4.5 Intercept Pharmaceuticals Recent Developments
10.5 Dr. Falk Pharma
10.5.1 Dr. Falk Pharma Basic Information
10.5.2 Dr. Falk Pharma Primary Sclerosing Cholangitis (Psc) Product Overview
10.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.5.4 Dr. Falk Pharma Business Overview
10.5.5 Dr. Falk Pharma Recent Developments
10.6 Allergan
10.6.1 Allergan Basic Information
10.6.2 Allergan Primary Sclerosing Cholangitis (Psc) Product Overview
10.6.3 Allergan Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.6.4 Allergan Business Overview
10.6.5 Allergan Recent Developments
10.7 Shire
10.7.1 Shire Basic Information
10.7.2 Shire Primary Sclerosing Cholangitis (Psc) Product Overview
10.7.3 Shire Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.7.4 Shire Business Overview
10.7.5 Shire Recent Developments
10.8 Durect Corporation
10.8.1 Durect Corporation Basic Information
10.8.2 Durect Corporation Primary Sclerosing Cholangitis (Psc) Product Overview
10.8.3 Durect Corporation Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.8.4 Durect Corporation Business Overview
10.8.5 Durect Corporation Recent Developments
10.9 Conatus Pharmaceuticals
10.9.1 Conatus Pharmaceuticals Basic Information
10.9.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
10.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.9.4 Conatus Pharmaceuticals Business Overview
10.9.5 Conatus Pharmaceuticals Recent Developments
10.10 Sirnaomics
10.10.1 Sirnaomics Basic Information
10.10.2 Sirnaomics Primary Sclerosing Cholangitis (Psc) Product Overview
10.10.3 Sirnaomics Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.10.4 Sirnaomics Business Overview
10.10.5 Sirnaomics Recent Developments
10.11 Shenzhen HighTide Biopharmaceutical
10.11.1 Shenzhen HighTide Biopharmaceutical Basic Information
10.11.2 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (Psc) Product Overview
10.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.11.4 Shenzhen HighTide Biopharmaceutical Business Overview
10.11.5 Shenzhen HighTide Biopharmaceutical Recent Developments
10.12 Glenmark
10.12.1 Glenmark Basic Information
10.12.2 Glenmark Primary Sclerosing Cholangitis (Psc) Product Overview
10.12.3 Glenmark Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.12.4 Glenmark Business Overview
10.12.5 Glenmark Recent Developments
10.13 Impax Laboratories
10.13.1 Impax Laboratories Basic Information
10.13.2 Impax Laboratories Primary Sclerosing Cholangitis (Psc) Product Overview
10.13.3 Impax Laboratories Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.13.4 Impax Laboratories Business Overview
10.13.5 Impax Laboratories Recent Developments
10.14 Mylan
10.14.1 Mylan Basic Information
10.14.2 Mylan Primary Sclerosing Cholangitis (Psc) Product Overview
10.14.3 Mylan Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.14.4 Mylan Business Overview
10.14.5 Mylan Recent Developments
10.15 Teva Pharmaceuticals
10.15.1 Teva Pharmaceuticals Basic Information
10.15.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
10.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.15.4 Teva Pharmaceuticals Business Overview
10.15.5 Teva Pharmaceuticals Recent Developments
10.16 Daewoong Pharmaceutical
10.16.1 Daewoong Pharmaceutical Basic Information
10.16.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (Psc) Product Overview
10.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.16.4 Daewoong Pharmaceutical Business Overview
10.16.5 Daewoong Pharmaceutical Recent Developments
10.17 Mitsubishi Tanabe Pharma
10.17.1 Mitsubishi Tanabe Pharma Basic Information
10.17.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (Psc) Product Overview
10.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.17.4 Mitsubishi Tanabe Pharma Business Overview
10.17.5 Mitsubishi Tanabe Pharma Recent Developments
10.18 Lannett
10.18.1 Lannett Basic Information
10.18.2 Lannett Primary Sclerosing Cholangitis (Psc) Product Overview
10.18.3 Lannett Primary Sclerosing Cholangitis (Psc) Product Market Performance
10.18.4 Lannett Business Overview
10.18.5 Lannett Recent Developments
11 PRIMARY SCLEROSING CHOLANGITIS (PSC) MARKET FORECAST BY REGION
11.1 Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast
11.2 Global Primary Sclerosing Cholangitis (Psc) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country
11.2.3 Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Region
11.2.4 South America Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Primary Sclerosing Cholangitis (Psc) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Primary Sclerosing Cholangitis (Psc) Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Primary Sclerosing Cholangitis (Psc) by Type (2026-2033)
12.1.2 Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Primary Sclerosing Cholangitis (Psc) by Type (2026-2033)
12.2 Global Primary Sclerosing Cholangitis (Psc) Market Forecast by Application (2026-2033)
12.2.1 Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) Forecast by Application
12.2.2 Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Primary Sclerosing Cholangitis (Psc) Market Size Comparison by Region (M USD)
Table 5. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) by Manufacturers (2020-2025)
Table 6. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Primary Sclerosing Cholangitis (Psc) Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Primary Sclerosing Cholangitis (Psc) Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis (Psc) as of 2024)
Table 10. Global Market Primary Sclerosing Cholangitis (Psc) Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Primary Sclerosing Cholangitis (Psc) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Primary Sclerosing Cholangitis (Psc) Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Primary Sclerosing Cholangitis (Psc) Sales by Type (K Units)
Table 26. Global Primary Sclerosing Cholangitis (Psc) Market Size by Type (M USD)
Table 27. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) by Type (2020-2025)
Table 28. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Type (2020-2025)
Table 29. Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) by Type (2020-2025)
Table 30. Global Primary Sclerosing Cholangitis (Psc) Market Size Share by Type (2020-2025)
Table 31. Global Primary Sclerosing Cholangitis (Psc) Price (USD/Unit) by Type (2020-2025)
Table 32. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) by Application
Table 33. Global Primary Sclerosing Cholangitis (Psc) Market Size by Application
Table 34. Global Primary Sclerosing Cholangitis (Psc) Sales by Application (2020-2025) & (K Units)
Table 35. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Application (2020-2025)
Table 36. Global Primary Sclerosing Cholangitis (Psc) Market Size by Application (2020-2025) & (M USD)
Table 37. Global Primary Sclerosing Cholangitis (Psc) Market Share by Application (2020-2025)
Table 38. Global Primary Sclerosing Cholangitis (Psc) Sales Growth Rate by Application (2020-2025)
Table 39. Global Primary Sclerosing Cholangitis (Psc) Sales by Region (2020-2025) & (K Units)
Table 40. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region (2020-2025)
Table 41. Global Primary Sclerosing Cholangitis (Psc) Market Size by Region (2020-2025) & (M USD)
Table 42. Global Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region (2020-2025)
Table 43. North America Primary Sclerosing Cholangitis (Psc) Sales by Country (2020-2025) & (K Units)
Table 44. North America Primary Sclerosing Cholangitis (Psc) Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Primary Sclerosing Cholangitis (Psc) Sales by Country (2020-2025) & (K Units)
Table 46. Europe Primary Sclerosing Cholangitis (Psc) Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales by Region (2020-2025) & (K Units)
Table 48. Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size by Region (2020-2025) & (M USD)
Table 49. South America Primary Sclerosing Cholangitis (Psc) Sales by Country (2020-2025) & (K Units)
Table 50. South America Primary Sclerosing Cholangitis (Psc) Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales by Region (2020-2025) & (K Units)
Table 52. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size by Region (2020-2025) & (M USD)
Table 53. Global Primary Sclerosing Cholangitis (Psc) Production (K Units) by Region(2020-2025)
Table 54. Global Primary Sclerosing Cholangitis (Psc) Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Primary Sclerosing Cholangitis (Psc) Revenue Market Share by Region (2020-2025)
Table 56. Global Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 57. North America Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. Europe Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Japan Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. China Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. Acorda Therapeutics Basic Information
Table 62. Acorda Therapeutics Primary Sclerosing Cholangitis (Psc) Product Overview
Table 63. Acorda Therapeutics Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 64. Acorda Therapeutics Business Overview
Table 65. Acorda Therapeutics SWOT Analysis
Table 66. Acorda Therapeutics Recent Developments
Table 67. Gilead Sciences Basic Information
Table 68. Gilead Sciences Primary Sclerosing Cholangitis (Psc) Product Overview
Table 69. Gilead Sciences Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 70. Gilead Sciences Business Overview
Table 71. Gilead Sciences SWOT Analysis
Table 72. Gilead Sciences Recent Developments
Table 73. NGM Biopharmaceuticals Basic Information
Table 74. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
Table 75. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. NGM Biopharmaceuticals Business Overview
Table 77. NGM Biopharmaceuticals SWOT Analysis
Table 78. NGM Biopharmaceuticals Recent Developments
Table 79. Intercept Pharmaceuticals Basic Information
Table 80. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
Table 81. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 82. Intercept Pharmaceuticals Business Overview
Table 83. Intercept Pharmaceuticals Recent Developments
Table 84. Dr. Falk Pharma Basic Information
Table 85. Dr. Falk Pharma Primary Sclerosing Cholangitis (Psc) Product Overview
Table 86. Dr. Falk Pharma Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. Dr. Falk Pharma Business Overview
Table 88. Dr. Falk Pharma Recent Developments
Table 89. Allergan Basic Information
Table 90. Allergan Primary Sclerosing Cholangitis (Psc) Product Overview
Table 91. Allergan Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 92. Allergan Business Overview
Table 93. Allergan Recent Developments
Table 94. Shire Basic Information
Table 95. Shire Primary Sclerosing Cholangitis (Psc) Product Overview
Table 96. Shire Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 97. Shire Business Overview
Table 98. Shire Recent Developments
Table 99. Durect Corporation Basic Information
Table 100. Durect Corporation Primary Sclerosing Cholangitis (Psc) Product Overview
Table 101. Durect Corporation Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 102. Durect Corporation Business Overview
Table 103. Durect Corporation Recent Developments
Table 104. Conatus Pharmaceuticals Basic Information
Table 105. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
Table 106. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 107. Conatus Pharmaceuticals Business Overview
Table 108. Conatus Pharmaceuticals Recent Developments
Table 109. Sirnaomics Basic Information
Table 110. Sirnaomics Primary Sclerosing Cholangitis (Psc) Product Overview
Table 111. Sirnaomics Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Sirnaomics Business Overview
Table 113. Sirnaomics Recent Developments
Table 114. Shenzhen HighTide Biopharmaceutical Basic Information
Table 115. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (Psc) Product Overview
Table 116. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 117. Shenzhen HighTide Biopharmaceutical Business Overview
Table 118. Shenzhen HighTide Biopharmaceutical Recent Developments
Table 119. Glenmark Basic Information
Table 120. Glenmark Primary Sclerosing Cholangitis (Psc) Product Overview
Table 121. Glenmark Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. Glenmark Business Overview
Table 123. Glenmark Recent Developments
Table 124. Impax Laboratories Basic Information
Table 125. Impax Laboratories Primary Sclerosing Cholangitis (Psc) Product Overview
Table 126. Impax Laboratories Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. Impax Laboratories Business Overview
Table 128. Impax Laboratories Recent Developments
Table 129. Mylan Basic Information
Table 130. Mylan Primary Sclerosing Cholangitis (Psc) Product Overview
Table 131. Mylan Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 132. Mylan Business Overview
Table 133. Mylan Recent Developments
Table 134. Teva Pharmaceuticals Basic Information
Table 135. Teva Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
Table 136. Teva Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 137. Teva Pharmaceuticals Business Overview
Table 138. Teva Pharmaceuticals Recent Developments
Table 139. Daewoong Pharmaceutical Basic Information
Table 140. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (Psc) Product Overview
Table 141. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 142. Daewoong Pharmaceutical Business Overview
Table 143. Daewoong Pharmaceutical Recent Developments
Table 144. Mitsubishi Tanabe Pharma Basic Information
Table 145. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (Psc) Product Overview
Table 146. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 147. Mitsubishi Tanabe Pharma Business Overview
Table 148. Mitsubishi Tanabe Pharma Recent Developments
Table 149. Lannett Basic Information
Table 150. Lannett Primary Sclerosing Cholangitis (Psc) Product Overview
Table 151. Lannett Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 152. Lannett Business Overview
Table 153. Lannett Recent Developments
Table 154. Global Primary Sclerosing Cholangitis (Psc) Sales Forecast by Region (2026-2033) & (K Units)
Table 155. Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Region (2026-2033) & (M USD)
Table 156. North America Primary Sclerosing Cholangitis (Psc) Sales Forecast by Country (2026-2033) & (K Units)
Table 157. North America Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country (2026-2033) & (M USD)
Table 158. Europe Primary Sclerosing Cholangitis (Psc) Sales Forecast by Country (2026-2033) & (K Units)
Table 159. Europe Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country (2026-2033) & (M USD)
Table 160. Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales Forecast by Region (2026-2033) & (K Units)
Table 161. Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Region (2026-2033) & (M USD)
Table 162. South America Primary Sclerosing Cholangitis (Psc) Sales Forecast by Country (2026-2033) & (K Units)
Table 163. South America Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country (2026-2033) & (M USD)
Table 164. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales Forecast by Country (2026-2033) & (Units)
Table 165. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country (2026-2033) & (M USD)
Table 166. Global Primary Sclerosing Cholangitis (Psc) Sales Forecast by Type (2026-2033) & (K Units)
Table 167. Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Type (2026-2033) & (M USD)
Table 168. Global Primary Sclerosing Cholangitis (Psc) Price Forecast by Type (2026-2033) & (USD/Unit)
Table 169. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) Forecast by Application (2026-2033)
Table 170. Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Application (2026-2033) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Primary Sclerosing Cholangitis (Psc) Market Size Comparison by Region (M USD)
Table 5. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) by Manufacturers (2020-2025)
Table 6. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Primary Sclerosing Cholangitis (Psc) Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Primary Sclerosing Cholangitis (Psc) Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis (Psc) as of 2024)
Table 10. Global Market Primary Sclerosing Cholangitis (Psc) Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Primary Sclerosing Cholangitis (Psc) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Primary Sclerosing Cholangitis (Psc) Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Primary Sclerosing Cholangitis (Psc) Sales by Type (K Units)
Table 26. Global Primary Sclerosing Cholangitis (Psc) Market Size by Type (M USD)
Table 27. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) by Type (2020-2025)
Table 28. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Type (2020-2025)
Table 29. Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) by Type (2020-2025)
Table 30. Global Primary Sclerosing Cholangitis (Psc) Market Size Share by Type (2020-2025)
Table 31. Global Primary Sclerosing Cholangitis (Psc) Price (USD/Unit) by Type (2020-2025)
Table 32. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) by Application
Table 33. Global Primary Sclerosing Cholangitis (Psc) Market Size by Application
Table 34. Global Primary Sclerosing Cholangitis (Psc) Sales by Application (2020-2025) & (K Units)
Table 35. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Application (2020-2025)
Table 36. Global Primary Sclerosing Cholangitis (Psc) Market Size by Application (2020-2025) & (M USD)
Table 37. Global Primary Sclerosing Cholangitis (Psc) Market Share by Application (2020-2025)
Table 38. Global Primary Sclerosing Cholangitis (Psc) Sales Growth Rate by Application (2020-2025)
Table 39. Global Primary Sclerosing Cholangitis (Psc) Sales by Region (2020-2025) & (K Units)
Table 40. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region (2020-2025)
Table 41. Global Primary Sclerosing Cholangitis (Psc) Market Size by Region (2020-2025) & (M USD)
Table 42. Global Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region (2020-2025)
Table 43. North America Primary Sclerosing Cholangitis (Psc) Sales by Country (2020-2025) & (K Units)
Table 44. North America Primary Sclerosing Cholangitis (Psc) Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Primary Sclerosing Cholangitis (Psc) Sales by Country (2020-2025) & (K Units)
Table 46. Europe Primary Sclerosing Cholangitis (Psc) Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales by Region (2020-2025) & (K Units)
Table 48. Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size by Region (2020-2025) & (M USD)
Table 49. South America Primary Sclerosing Cholangitis (Psc) Sales by Country (2020-2025) & (K Units)
Table 50. South America Primary Sclerosing Cholangitis (Psc) Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales by Region (2020-2025) & (K Units)
Table 52. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size by Region (2020-2025) & (M USD)
Table 53. Global Primary Sclerosing Cholangitis (Psc) Production (K Units) by Region(2020-2025)
Table 54. Global Primary Sclerosing Cholangitis (Psc) Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Primary Sclerosing Cholangitis (Psc) Revenue Market Share by Region (2020-2025)
Table 56. Global Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 57. North America Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. Europe Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. Japan Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. China Primary Sclerosing Cholangitis (Psc) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 61. Acorda Therapeutics Basic Information
Table 62. Acorda Therapeutics Primary Sclerosing Cholangitis (Psc) Product Overview
Table 63. Acorda Therapeutics Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 64. Acorda Therapeutics Business Overview
Table 65. Acorda Therapeutics SWOT Analysis
Table 66. Acorda Therapeutics Recent Developments
Table 67. Gilead Sciences Basic Information
Table 68. Gilead Sciences Primary Sclerosing Cholangitis (Psc) Product Overview
Table 69. Gilead Sciences Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 70. Gilead Sciences Business Overview
Table 71. Gilead Sciences SWOT Analysis
Table 72. Gilead Sciences Recent Developments
Table 73. NGM Biopharmaceuticals Basic Information
Table 74. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
Table 75. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. NGM Biopharmaceuticals Business Overview
Table 77. NGM Biopharmaceuticals SWOT Analysis
Table 78. NGM Biopharmaceuticals Recent Developments
Table 79. Intercept Pharmaceuticals Basic Information
Table 80. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
Table 81. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 82. Intercept Pharmaceuticals Business Overview
Table 83. Intercept Pharmaceuticals Recent Developments
Table 84. Dr. Falk Pharma Basic Information
Table 85. Dr. Falk Pharma Primary Sclerosing Cholangitis (Psc) Product Overview
Table 86. Dr. Falk Pharma Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. Dr. Falk Pharma Business Overview
Table 88. Dr. Falk Pharma Recent Developments
Table 89. Allergan Basic Information
Table 90. Allergan Primary Sclerosing Cholangitis (Psc) Product Overview
Table 91. Allergan Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 92. Allergan Business Overview
Table 93. Allergan Recent Developments
Table 94. Shire Basic Information
Table 95. Shire Primary Sclerosing Cholangitis (Psc) Product Overview
Table 96. Shire Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 97. Shire Business Overview
Table 98. Shire Recent Developments
Table 99. Durect Corporation Basic Information
Table 100. Durect Corporation Primary Sclerosing Cholangitis (Psc) Product Overview
Table 101. Durect Corporation Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 102. Durect Corporation Business Overview
Table 103. Durect Corporation Recent Developments
Table 104. Conatus Pharmaceuticals Basic Information
Table 105. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
Table 106. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 107. Conatus Pharmaceuticals Business Overview
Table 108. Conatus Pharmaceuticals Recent Developments
Table 109. Sirnaomics Basic Information
Table 110. Sirnaomics Primary Sclerosing Cholangitis (Psc) Product Overview
Table 111. Sirnaomics Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Sirnaomics Business Overview
Table 113. Sirnaomics Recent Developments
Table 114. Shenzhen HighTide Biopharmaceutical Basic Information
Table 115. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (Psc) Product Overview
Table 116. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 117. Shenzhen HighTide Biopharmaceutical Business Overview
Table 118. Shenzhen HighTide Biopharmaceutical Recent Developments
Table 119. Glenmark Basic Information
Table 120. Glenmark Primary Sclerosing Cholangitis (Psc) Product Overview
Table 121. Glenmark Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. Glenmark Business Overview
Table 123. Glenmark Recent Developments
Table 124. Impax Laboratories Basic Information
Table 125. Impax Laboratories Primary Sclerosing Cholangitis (Psc) Product Overview
Table 126. Impax Laboratories Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. Impax Laboratories Business Overview
Table 128. Impax Laboratories Recent Developments
Table 129. Mylan Basic Information
Table 130. Mylan Primary Sclerosing Cholangitis (Psc) Product Overview
Table 131. Mylan Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 132. Mylan Business Overview
Table 133. Mylan Recent Developments
Table 134. Teva Pharmaceuticals Basic Information
Table 135. Teva Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Product Overview
Table 136. Teva Pharmaceuticals Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 137. Teva Pharmaceuticals Business Overview
Table 138. Teva Pharmaceuticals Recent Developments
Table 139. Daewoong Pharmaceutical Basic Information
Table 140. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (Psc) Product Overview
Table 141. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 142. Daewoong Pharmaceutical Business Overview
Table 143. Daewoong Pharmaceutical Recent Developments
Table 144. Mitsubishi Tanabe Pharma Basic Information
Table 145. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (Psc) Product Overview
Table 146. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 147. Mitsubishi Tanabe Pharma Business Overview
Table 148. Mitsubishi Tanabe Pharma Recent Developments
Table 149. Lannett Basic Information
Table 150. Lannett Primary Sclerosing Cholangitis (Psc) Product Overview
Table 151. Lannett Primary Sclerosing Cholangitis (Psc) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 152. Lannett Business Overview
Table 153. Lannett Recent Developments
Table 154. Global Primary Sclerosing Cholangitis (Psc) Sales Forecast by Region (2026-2033) & (K Units)
Table 155. Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Region (2026-2033) & (M USD)
Table 156. North America Primary Sclerosing Cholangitis (Psc) Sales Forecast by Country (2026-2033) & (K Units)
Table 157. North America Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country (2026-2033) & (M USD)
Table 158. Europe Primary Sclerosing Cholangitis (Psc) Sales Forecast by Country (2026-2033) & (K Units)
Table 159. Europe Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country (2026-2033) & (M USD)
Table 160. Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales Forecast by Region (2026-2033) & (K Units)
Table 161. Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Region (2026-2033) & (M USD)
Table 162. South America Primary Sclerosing Cholangitis (Psc) Sales Forecast by Country (2026-2033) & (K Units)
Table 163. South America Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country (2026-2033) & (M USD)
Table 164. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales Forecast by Country (2026-2033) & (Units)
Table 165. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Country (2026-2033) & (M USD)
Table 166. Global Primary Sclerosing Cholangitis (Psc) Sales Forecast by Type (2026-2033) & (K Units)
Table 167. Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Type (2026-2033) & (M USD)
Table 168. Global Primary Sclerosing Cholangitis (Psc) Price Forecast by Type (2026-2033) & (USD/Unit)
Table 169. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) Forecast by Application (2026-2033)
Table 170. Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Application (2026-2033) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Primary Sclerosing Cholangitis (Psc)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD), 2024-2033
Figure 5. Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) (2020-2033)
Figure 6. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Primary Sclerosing Cholangitis (Psc) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Primary Sclerosing Cholangitis (Psc) Product Life Cycle
Figure 13. Primary Sclerosing Cholangitis (Psc) Sales Share by Manufacturers in 2024
Figure 14. Global Primary Sclerosing Cholangitis (Psc) Revenue Share by Manufacturers in 2024
Figure 15. Primary Sclerosing Cholangitis (Psc) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Primary Sclerosing Cholangitis (Psc) Average Price (USD/Unit) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Primary Sclerosing Cholangitis (Psc) Revenue in 2024
Figure 18. Industry Chain Map of Primary Sclerosing Cholangitis (Psc)
Figure 19. Global Primary Sclerosing Cholangitis (Psc) Market PEST Analysis
Figure 20. Global Primary Sclerosing Cholangitis (Psc) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Primary Sclerosing Cholangitis (Psc) Market Share by Type
Figure 27. Sales Market Share of Primary Sclerosing Cholangitis (Psc) by Type (2020-2025)
Figure 28. Sales Market Share of Primary Sclerosing Cholangitis (Psc) by Type in 2024
Figure 29. Market Size Share of Primary Sclerosing Cholangitis (Psc) by Type (2020-2025)
Figure 30. Market Size Share of Primary Sclerosing Cholangitis (Psc) by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Primary Sclerosing Cholangitis (Psc) Market Share by Application
Figure 33. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Application (2020-2025)
Figure 34. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Application in 2024
Figure 35. Global Primary Sclerosing Cholangitis (Psc) Market Share by Application (2020-2025)
Figure 36. Global Primary Sclerosing Cholangitis (Psc) Market Share by Application in 2024
Figure 37. Global Primary Sclerosing Cholangitis (Psc) Sales Growth Rate by Application (2020-2025)
Figure 38. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region (2020-2025)
Figure 39. Global Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region (2020-2025)
Figure 40. North America Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Primary Sclerosing Cholangitis (Psc) Sales Market Share by Country in 2024
Figure 43. North America Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Country in 2024
Figure 45. U.S. Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Primary Sclerosing Cholangitis (Psc) Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Primary Sclerosing Cholangitis (Psc) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Primary Sclerosing Cholangitis (Psc) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Primary Sclerosing Cholangitis (Psc) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Primary Sclerosing Cholangitis (Psc) Sales Market Share by Country in 2024
Figure 53. Europe Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Country in 2024
Figure 55. Germany Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region in 2024
Figure 67. Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region in 2024
Figure 68. China Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (K Units)
Figure 79. South America Primary Sclerosing Cholangitis (Psc) Sales Market Share by Country in 2024
Figure 80. South America Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (M USD)
Figure 81. South America Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Country in 2024
Figure 82. Brazil Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Primary Sclerosing Cholangitis (Psc) Production Market Share by Region (2020-2025)
Figure 103. North America Primary Sclerosing Cholangitis (Psc) Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Primary Sclerosing Cholangitis (Psc) Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Primary Sclerosing Cholangitis (Psc) Production (K Units) Growth Rate (2020-2025)
Figure 106. China Primary Sclerosing Cholangitis (Psc) Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Primary Sclerosing Cholangitis (Psc) Sales Forecast by Volume (2020-2033) & (K Units)
Figure 108. Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Primary Sclerosing Cholangitis (Psc) Market Share Forecast by Type (2026-2033)
Figure 111. Global Primary Sclerosing Cholangitis (Psc) Sales Forecast by Application (2026-2033)
Figure 112. Global Primary Sclerosing Cholangitis (Psc) Market Share Forecast by Application (2026-2033)
Figure 1. Product Picture of Primary Sclerosing Cholangitis (Psc)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD), 2024-2033
Figure 5. Global Primary Sclerosing Cholangitis (Psc) Market Size (M USD) (2020-2033)
Figure 6. Global Primary Sclerosing Cholangitis (Psc) Sales (K Units) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Primary Sclerosing Cholangitis (Psc) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Primary Sclerosing Cholangitis (Psc) Product Life Cycle
Figure 13. Primary Sclerosing Cholangitis (Psc) Sales Share by Manufacturers in 2024
Figure 14. Global Primary Sclerosing Cholangitis (Psc) Revenue Share by Manufacturers in 2024
Figure 15. Primary Sclerosing Cholangitis (Psc) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Primary Sclerosing Cholangitis (Psc) Average Price (USD/Unit) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Primary Sclerosing Cholangitis (Psc) Revenue in 2024
Figure 18. Industry Chain Map of Primary Sclerosing Cholangitis (Psc)
Figure 19. Global Primary Sclerosing Cholangitis (Psc) Market PEST Analysis
Figure 20. Global Primary Sclerosing Cholangitis (Psc) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Primary Sclerosing Cholangitis (Psc) Market Share by Type
Figure 27. Sales Market Share of Primary Sclerosing Cholangitis (Psc) by Type (2020-2025)
Figure 28. Sales Market Share of Primary Sclerosing Cholangitis (Psc) by Type in 2024
Figure 29. Market Size Share of Primary Sclerosing Cholangitis (Psc) by Type (2020-2025)
Figure 30. Market Size Share of Primary Sclerosing Cholangitis (Psc) by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Primary Sclerosing Cholangitis (Psc) Market Share by Application
Figure 33. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Application (2020-2025)
Figure 34. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Application in 2024
Figure 35. Global Primary Sclerosing Cholangitis (Psc) Market Share by Application (2020-2025)
Figure 36. Global Primary Sclerosing Cholangitis (Psc) Market Share by Application in 2024
Figure 37. Global Primary Sclerosing Cholangitis (Psc) Sales Growth Rate by Application (2020-2025)
Figure 38. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region (2020-2025)
Figure 39. Global Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region (2020-2025)
Figure 40. North America Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Primary Sclerosing Cholangitis (Psc) Sales Market Share by Country in 2024
Figure 43. North America Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Country in 2024
Figure 45. U.S. Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Primary Sclerosing Cholangitis (Psc) Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Primary Sclerosing Cholangitis (Psc) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Primary Sclerosing Cholangitis (Psc) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Primary Sclerosing Cholangitis (Psc) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Primary Sclerosing Cholangitis (Psc) Sales Market Share by Country in 2024
Figure 53. Europe Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Country in 2024
Figure 55. Germany Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region in 2024
Figure 67. Asia Pacific Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region in 2024
Figure 68. China Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (K Units)
Figure 79. South America Primary Sclerosing Cholangitis (Psc) Sales Market Share by Country in 2024
Figure 80. South America Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (M USD)
Figure 81. South America Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Country in 2024
Figure 82. Brazil Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Primary Sclerosing Cholangitis (Psc) Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Primary Sclerosing Cholangitis (Psc) Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Primary Sclerosing Cholangitis (Psc) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Primary Sclerosing Cholangitis (Psc) Production Market Share by Region (2020-2025)
Figure 103. North America Primary Sclerosing Cholangitis (Psc) Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Primary Sclerosing Cholangitis (Psc) Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Primary Sclerosing Cholangitis (Psc) Production (K Units) Growth Rate (2020-2025)
Figure 106. China Primary Sclerosing Cholangitis (Psc) Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Primary Sclerosing Cholangitis (Psc) Sales Forecast by Volume (2020-2033) & (K Units)
Figure 108. Global Primary Sclerosing Cholangitis (Psc) Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Primary Sclerosing Cholangitis (Psc) Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Primary Sclerosing Cholangitis (Psc) Market Share Forecast by Type (2026-2033)
Figure 111. Global Primary Sclerosing Cholangitis (Psc) Sales Forecast by Application (2026-2033)
Figure 112. Global Primary Sclerosing Cholangitis (Psc) Market Share Forecast by Application (2026-2033)
